Drug makers took a hit after Pfizer announced highly promising results from tests of a pill to treat Covid-19, knocking the market more broadly and taking the Kospi down for the day.
SK Bioscience’s Covid-19 vaccine candidate demonstrated statistically meaningful results confirming safety and immunogenicity in Phase 1 and 2 clinical trials.
Korean biopharmaceutical companies are enjoying a strong third quarter on the lingering Covid-19 pandemic and sales of vaccines they produce under contract manufacturing organization (CMO) deals.
SK Bioscience is set to speed up its global Phase 3 clinical trials of its GBP510 Covid-19 vaccine candidate.
SK Bioscience has agreed to extend its contract with Coalition for Epidemic Preparedness Innovations (CEPI) for use of its manufacturing capacities for Covid-19 vaccines for another year, the Korean vaccine maker said Wednesday.
KakaoBank slipped for a third day on Monday with some institutional investors offloading shares as the agreed lockup period ends.
Korean drugmaker SK Bioscience said Monday it has begun the phase three clinical trial of its Covid-19 vaccine candidate.
SK Bioscience’s Covid-19 vaccine candidate GBP510 won approval to start Phase 3 clinical trials, the company said Tuesday.
Making Korea a global hub of vaccine production, one of the goals laid out by President Moon Jae-in, is very slowly becoming a reality with domestic biotech companies’ growing presence in contract manufacturing organization (CMO) market.
SK Bioscience, a contract manufacturer of Covid-19 vaccines developed by AstraZeneca and Novavax, will spend 150 billion won ($132 million) by 2024 to ramp up the production capacity of its facility in Andong, North Gyeongsang.